Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Paid Sick Leave Could Ease Burden for Colorectal Cancer Patients

January 1, 2016
By Anna Azvolinsky
Article

Paid sick leave benefits could alleviate some of the financial burden patients with colorectal cancer incur during treatment and boost their job retention.

Paid sick leave benefits could alleviate some of the financial burden patients with colorectal cancer (CRC) incur during treatment and boost their job retention, according to a survey-based study published in JAMA.

Christine M. Veenstra, MD, MSHP, a medical oncologist specializing in colorectal cancer at the University of Michigan, and colleagues analyzed mail and telephone surveys of patients with stage III CRC between 2011 and 2013.

The survey found that 55% of CRC patients retained their jobs following their cancer diagnosis; 59% of survey responders with paid sick leave retained their job through their treatment compared with 33% of those who did not have paid sick leave (P < .001).

Patients who were able to retain their jobs were more likely to be men, married, white, and without other illnesses. They were also more likely to be educated and to have a higher annual income and private health insurance.

Patients who did not have access to paid leave reported significantly higher personal financial burden compared with those who did not receive paid leave, including the need to borrow money (28% vs 18%; P < .001), difficulties making credit card payments (29% vs 14%; P < .001), and reduced spending on food and clothing (50% vs 35%; P < .001).

Patients in the study filled out surveys 4 months prior to cancer treatment and 12 months following treatment. Job retention was defined as employment at both diagnosis and a mean of 8 months following diagnosis.

Of the 567 patients who responded to the survey, 56% had paid sick leave from their employer. Of the responders, 58% were male, 28% had less than a high school education, and 35% reported an annual household income of less than $50,000.

As many as 40% of workers in the Unites States do not have paid sick leave from their employer and sick leave is not mandated under the Affordable Care Act or the Family and Medical Leave Act. Such a benefit is also not part of health insurance coverage in the United States. The study suggests that there are significant negative consequences for workers who do not have access to paid sick leave and are diagnosed with serious health conditions such as CRC.

The limitations of the study are that the data analyzed came only from those who responded to the survey and that data on the specific reasons for job change or loss was not captured.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
Advertisement

Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment

Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment

Tim Cortese
May 22nd 2025
Article

Survival and safety data from the phase 3 CheckMate 9DW trial showed that nivolumab plus ipilimumab was superior to lenvatinib or sorafenib in advanced HCC.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

Roman Fabbricatore
May 19th 2025
Article

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy in this squamous cell carcinoma of the anal canal population.

FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer

Russ Conroy
May 15th 2025
Article

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.


The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

Related Content
Advertisement

Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment

Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment

Tim Cortese
May 22nd 2025
Article

Survival and safety data from the phase 3 CheckMate 9DW trial showed that nivolumab plus ipilimumab was superior to lenvatinib or sorafenib in advanced HCC.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

Roman Fabbricatore
May 19th 2025
Article

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy in this squamous cell carcinoma of the anal canal population.

FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer

Russ Conroy
May 15th 2025
Article

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.


The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.